Property and Equipment
|12 Months Ended|
Dec. 31, 2020
|Property, Plant and Equipment [Abstract]|
|Property and Equipment||Property and Equipment
Property and equipment consisted of the following (in thousands):
As of December 31, 2020 and 2019, the Company had $0.3 million and $0.7 million, respectively, of lab equipment, net, in the field at clinical trial sites and held by a vendor for final testing. Depreciation of this equipment started when it was placed in service in June 2019. During the year ended December 31, 2020, the Company wrote-down lab equipment by $0.3 million and included it in the write-down of intangible assets and equipment line item in the accompanying statement of operations.
Depreciation expense for the years ended December 31, 2020 and 2019 was $0.3 million and $0.2 million, respectively.
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef